Pricing Log in Create free account

MiNK Therapeutics, Inc. (INKT) vs Kalaris Therapeutics Inc. (KLRS)

MiNK Therapeutics, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. MiNK Therapeutics, Inc. and Kalaris Therapeutics Inc. are of similar size ($51.6M and $51.3M). Across the 7 metrics below, MiNK Therapeutics, Inc. leads on 4 and Kalaris Therapeutics Inc. on 3.

Valuation

Metric INKT KLRS Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B n/m 1.01 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.33 0.66
EV/Sales n/m n/m 9.02
Earnings yield (23.19%) (85.64%) (32.88%)
Free cash flow yield (13.28%) (70.40%) (23.13%)

Profitability

Metric INKT KLRS Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 57.94% (79.91%) (51.96%)
Return on assets (187.78%) (46.02%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INKT KLRS Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (2.45%) 94.50% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INKT KLRS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.23 10.98 4.97
Net debt to EBITDA 1.07 2.54 1.01

Dividend

Metric INKT KLRS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INKT KLRS Biotechnology median
Market cap 51.28m 51.55m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack